Final epitopes of vaccine construct.

<div><p>Human parechovirus (HPeV) is widely recognized as a severe viral infection affecting infants and neonates. Belonging to the <i>Picornaviridae</i> family, HPeV is categorized into 19 distinct genotypes. Among them, HPeV-1 is the most prevalent genotype, primarily associated with respiratory and digestive symptoms. Considering HPeV’s role as a leading cause of life-threatening viral infections in infants and the lack of effective antiviral therapies, our focus centered on developing two multi-epitope vaccines, namely HPeV-Vax-1 and HPeV-Vax-2, using advanced immunoinformatic techniques. Multi-epitope vaccines have the advantage of protecting against various virus strains and may be preferable to live attenuated vaccines. Using the NCBI database, three viral protein sequences (VP0, VP1, and VP3) from six HPeV strains were collected to construct consensus protein sequences. Then the antigenicity, toxicity, allergenicity, and stability were analyzed after discovering T-cell and linear B-cell epitopes from the protein sequences. The fundamental structures of the vaccines were produced by fusing the selected epitopes with appropriate linkers and adjuvants. Comprehensive physicochemical, antigenic, allergic assays, and disulfide engineering demonstrated the effectiveness of the vaccines. Further refinement of secondary and tertiary models for both vaccines revealed promising interactions with toll-like receptor 4 (TLR4) in molecular docking, further confirmed by molecular dynamics simulation. <i>In silico</i> immunological modeling was employed to assess the vaccine’s capacity to stimulate an immune reaction. <i>In silico</i> immunological simulations were employed to evaluate the vaccines’ ability to trigger an immune response. Codon optimization and <i>in silico</i> cloning analyses showed that <i>Escherichia coli (E</i>. <i>coli)</i> was most likely the host for the candidate vaccines. Our findings suggest that these multi-epitope vaccines could be the potential HPeV vaccines and are recommended for further wet-lab investigation.</p></div>

Publication Details

Journal
Figshare
Published
2024-12-04
DOI
https://doi.org/10.1371/journal.pone.0302120.s011
Primary Topic
vaccines and immunoinformatics approaches
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Final epitopes of vaccine construct.

Figshare
vaccines and immunoinformatics approaches
article

Final epitopes of vaccine construct.

article en

Abstract

<div><p>Human parechovirus (HPeV) is widely recognized as a severe viral infection affecting infants and neonates. Belonging to the <i>Picornaviridae</i> family, HPeV is categorized into 19 distinct genotypes. Among them, HPeV-1 is the most prevalent genotype, primarily associated with respiratory and digestive symptoms. Considering HPeV’s role as a leading cause of life-threatening viral infections in infants and the lack of effective antiviral therapies, our focus centered on developing two multi-epitope vaccines, namely HPeV-Vax-1 and HPeV-Vax-2, using advanced immunoinformatic techniques. Multi-epitope vaccines have the advantage of protecting against various virus strains and may be preferable to live attenuated vaccines. Using the NCBI database, three viral protein sequences (VP0, VP1, and VP3) from six HPeV strains were collected to construct consensus protein sequences. Then the antigenicity, toxicity, allergenicity, and stability were analyzed after discovering T-cell and linear B-cell epitopes from the protein sequences. The fundamental structures of the vaccines were produced by fusing the selected epitopes with appropriate linkers and adjuvants. Comprehensive physicochemical, antigenic, allergic assays, and disulfide engineering demonstrated the effectiveness of the vaccines. Further refinement of secondary and tertiary models for both vaccines revealed promising interactions with toll-like receptor 4 (TLR4) in molecular docking, further confirmed by molecular dynamics simulation. <i>In silico</i> immunological modeling was employed to assess the vaccine’s capacity to stimulate an immune reaction. <i>In silico</i> immunological simulations were employed to evaluate the vaccines’ ability to trigger an immune response. Codon optimization and <i>in silico</i> cloning analyses showed that <i>Escherichia coli (E</i>. <i>coli)</i> was most likely the host for the candidate vaccines. Our findings suggest that these multi-epitope vaccines could be the potential HPeV vaccines and are recommended for further wet-lab investigation.</p></div>

Figshare
Openalex Percentile: Top 72%
vaccines and immunoinformatics approaches
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Final epitopes of vaccine construct. · Figshare (2024) | TGRS Research Map | TGRS